{"id":"https://openalex.org/W2393342002","doi":null,"title":"A Double-Blind Double-Dummy Randomized Controlled Multicenter Clinical Trial on Toterodine Versus Oxybutynin in the Treatment of Overactive Bladder","display_name":"A Double-Blind Double-Dummy Randomized Controlled Multicenter Clinical Trial on Toterodine Versus Oxybutynin in the Treatment of Overactive Bladder","alternate_titles":[],"publication_year":2001,"publication_date":"2001-01-01","ids":{"openalex":"https://openalex.org/W2393342002","mag":"2393342002"},"language":"en","primary_location":{"id":"mag:2393342002","doi":null,"is_oa":false,"landing_page_url":"https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ200105003","pdf_url":null,"source":{"id":"https://openalex.org/S2764396500","display_name":"The Chinese Journal of Clinical Pharmacology","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4320800687","host_organization_name":"Chinese Pharmaceutical Association","host_organization_lineage":["https://openalex.org/P4320800687"],"host_organization_lineage_names":["Chinese Pharmaceutical Association"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"The Chinese Journal of Clinical Pharmacology","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2393342002"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5101554646","display_name":"Shengxian Wu","orcid":"https://orcid.org/0000-0002-6034-9728","observed_orcids":["https://orcid.org/0000-0002-6034-9728"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Shengxian Wu","raw_affiliation_strings":["Hi-Liang, CUI Yi-Min, YANG Yong, DUAN Ji-Hong, NA Yan-Qun, XU ZHi-SHun,  CHENG Ji-Yi, CAI Song-Liang, QIN Da-SHan, SUN Yu-CHeng, GUO Ying-Lu"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hi-Liang, CUI Yi-Min, YANG Yong, DUAN Ji-Hong, NA Yan-Qun, XU ZHi-SHun,  CHENG Ji-Yi, CAI Song-Liang, QIN Da-SHan, SUN Yu-CHeng, GUO Ying-Lu","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5101554646"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10418","display_name":"Pelvic floor disorders treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.8709999918937683},{"id":"https://openalex.org/keywords/tolterodine","display_name":"tolterodine","score":0.9980000257492065},{"id":"https://openalex.org/keywords/oxybutynin","display_name":"oxybutynin","score":1.0},{"id":"https://openalex.org/keywords/anticholinergic-drugs","display_name":"anticholinergic agents","score":0.8460000157356262},{"id":"https://openalex.org/keywords/urinary-incontinence","display_name":"urinary incontinence","score":0.8080000281333923},{"id":"https://openalex.org/keywords/micturition-frequency","display_name":"micturition frequency","score":0.8970000147819519},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.7649999856948853},{"id":"https://openalex.org/keywords/xerostomia","display_name":"xerostomia","score":0.9300000071525574},{"id":"https://openalex.org/keywords/comparative-efficacy","display_name":"drug efficacy comparison","score":0.7369999885559082}],"concepts":[{"id":"https://openalex.org/C2781020410","wikidata":"https://www.wikidata.org/wiki/Q424312","display_name":"Tolterodine","level":4,"score":0.9900870323181152},{"id":"https://openalex.org/C2777844464","wikidata":"https://www.wikidata.org/wiki/Q1060922","display_name":"Oxybutynin","level":4,"score":0.9552263617515564},{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.8761407732963562},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7471818923950195},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.6551657915115356},{"id":"https://openalex.org/C175768497","wikidata":"https://www.wikidata.org/wiki/Q105726","display_name":"Urination","level":3,"score":0.592247486114502},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.5759036540985107},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5678832530975342},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.45207759737968445},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.32030969858169556},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.28414186835289},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.22256067395210266},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2393342002","doi":null,"is_oa":false,"landing_page_url":"https://oversea.cnki.net/kcms/detail/detail.aspx?dbcode=CJFD&filename=GLYZ200105003","pdf_url":null,"source":{"id":"https://openalex.org/S2764396500","display_name":"The Chinese Journal of Clinical Pharmacology","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/P4320800687","host_organization_name":"Chinese Pharmaceutical Association","host_organization_lineage":["https://openalex.org/P4320800687"],"host_organization_lineage_names":["Chinese Pharmaceutical Association"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"The Chinese Journal of Clinical Pharmacology","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2377958226","https://openalex.org/W2382578058","https://openalex.org/W2008079238","https://openalex.org/W2024975356","https://openalex.org/W2388515924","https://openalex.org/W2056717611","https://openalex.org/W2088679190","https://openalex.org/W1997727859","https://openalex.org/W2058646317","https://openalex.org/W1821426726"],"abstract_inverted_index":{"OBJECTIVE:":[0],"To":[1],"evaluate":[2],"the":[3,50,57,68,86,89,98,103,111,114,146,161],"efficacy":[4,148],"and":[5,67,82,97,118,126,160],"tolerability":[6],"of":[7,53,55,60,71,92,100,123,163],"tolterodine":[8,36,80,87,134,164],"in":[9,77,110,131,136],"patients":[10,27,150],"with":[11,28,65,151],"an":[12],"overactive":[13,152],"bladder.":[14],"METHODS:":[15],"A":[16],"double-blind":[17],"double-dummy":[18],"randomized":[19],"controlled":[20],"multicenter":[21],"clinical":[22],"trial":[23],"was":[24,95,107],"designed.":[25],"237":[26],"bladder":[29,153],"overactivity":[30],"were":[31,74,116,128,165],"enrolled,":[32],"Patients":[33],"received":[34],"either":[35],"(2mg":[37],"twice":[38,43,143,158],"daily)":[39],"or":[40],"oxybutynin":[41,83,112,156],"(5mg":[42],"daily).":[44],"RESULTS:":[45],"After":[46],"6":[47],"weeks'":[48],"treatment,":[49],"mean":[51,58],"decrease":[52,59],"frequency":[54],"micturition,":[56],"incontinence":[61,66],"episodes":[62],"among":[63],"those":[64,78,132,137],"volume":[69],"increase":[70],"every":[72],"micturition":[73],"statistically":[75],"equivalent":[76,147],"receiving":[79],"(n=109)":[81],"(n=108).":[84],"In":[85],"group,":[88,113],"total":[90],"incidence":[91,99],"adverse":[93,124],"event":[94],"48.2%":[96],"dry":[101],"mouth,":[102],"most":[104],"common":[105],"adverse,":[106],"32.5%.":[108],"While":[109],"incidences":[115,122],"65.0%":[117],"55.3%,":[119],"respectively.":[120],"The":[121],"events":[125],"dryness":[127],"significantly":[129],"lower":[130,166],"on":[133,138,149],"than":[135,167],"oxybutynin.":[139,168],"CONCLUSIONS:":[140],"Tolterodine":[141],"2mg":[142],"daily":[144],"had":[145],"compared":[154],"to":[155],"5mg":[157],"daily,":[159],"adverse-effection":[162]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2393342002","counts_by_year":[],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
